Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation
Open Access
- 1 June 2020
- journal article
- research article
- Published by Wiley in European Journal of Oral Sciences
- Vol. 128 (3), 204-210
- https://doi.org/10.1111/eos.12689
Abstract
Radioiodine (I-131, RAI) has traditionally been used in thyroid cancer treatment but its benefit should be balanced against possible risks. Among them, salivary gland dysfunction has often been discussed, although the reported data have been inconsistent. The aim of our prospective study was to evaluate salivary gland function in 31 thyroidectomised patients (6 men, 25 women; median age 52 yr) before and 4-6 months after RAI remnant ablation (RRA), using activity of 3.7 GBq I-131-NaI. Salivary gland uptake and excretion fractions were quantitatively assessed with Tc-99m - pertechnetate salivary gland scintigraphy. Pre- and post-treatment values were compared using Wilcoxon signed rank test. No statistically significant difference in the pre- and post-treatment values was observed in parotid or submandibular glands uptake, or in the parotid or submandibular excretion fractions. The calculated power for minimum relevant difference of 25% with the sample size of 31 ranged between 86% and 96% for the individual variables, making our negative results reasonably reliable. The results suggest that RRA with the most commonly used activity of 3.7 GBq has no important impact on salivary gland function. Therefore, the concerns about putative salivary gland functional deterioration following RRA are probably unjustified.Funding Information
- Univerzita Karlova v Praze (Q40‐14 and Q40-08)
This publication has 40 references indexed in Scilit:
- SPECT/CT localization of oral radioiodine activityNuclear Medicine Communications, 2013
- Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid CancerThe New England Journal of Medicine, 2012
- Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid CancerThe New England Journal of Medicine, 2012
- Clinical Management of Salivary Gland Hypofunction and Xerostomia in Head-and-Neck Cancer Patients: Successes and BarriersInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCiThyroid Research, 2010
- Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine AblationJournal of Nuclear Medicine, 2009
- The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort StudyJournal of Nuclear Medicine, 2007
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- 99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl- co-transport system.JCI Insight, 1987